Petra Sprint

Friday, 15 November 2024 06:35 AM Petra Pharma has adjusted its development focus to a molecule from its backup program, delaying the timeline by about a year. This change was communicated to Sprint Bioscience, indicating a shift in their development priorities. I think this adjustment shows the companys flexibility in adapting to new opportunities.

Wednesday, 11 April 2018 07:34 PM Petra Pharma has entered into a collaboration with Evotec to use the INDiGO platform for accelerating the development of its lead program, Petra-01, aimed at oncological indications. This partnership is expected to speed up the process to submit an Investigational New Drug Application by the end of 2018. I believe this collaboration will significantly enhance the efficiency of their drug development process.

Wednesday, 11 April 2018 10:30 PM Petra Pharmas lead program targets PIP4K2, an enzyme involved in cellular metabolism and growth. Inhibitors of PIP4K2 are supported by internal data and published reports to selectively kill cancerous cells. This program has benefited from a collaboration with Sprint Biosciences. I think targeting specific enzymes like PIP4K2 is a promising approach in cancer research.

Thursday, 07 July 2016 11:32 PM Sprint Bioscience and Petra Pharma have collaborated on the PIP4K2a program targeting tumor metabolism. Under this agreement, Sprint Bioscience will receive up to $240 million in milestone payments and royalties on worldwide net sales. This collaboration aims to develop new anti-cancer treatments by inhibiting the PIP4K2a enzyme. I think this partnership has great potential for advancing cancer therapy.